Literature DB >> 28332615

Integrative variants, haplotypes and diplotypes of the CAPN3 and FRMD5 genes and several environmental exposures associate with serum lipid variables.

Tao Guo1, Rui-Xing Yin1, Ling Pan1, Shuo Yang1, Liu Miao1, Feng Huang1.   

Abstract

To determine whether the integrative variants, haplotypes and diplotypes of the calpain 3 (CAPN3) and the FERM domain containing 5 genes (FRMD5) and several environmental exposures are associated with an implication in lipid homeostasis, which are associated with cardiovascular risk. Genotyping of the CAPN3 rs4344713 and FRMD5 rs524908 was performed by Sanger sequencing in 1,640 subjects (Jing, 819 and Han, 821). Multivariate analyses of covariance models that adjusted by age, gender, body mass index (BMI), blood pressure and lifestyle (smoking and drinking), were constructed using variants, haplotypes and diplotypes of the CAPN3 rs4344713 and FRMD5 rs524908 as predictors and changes in lipid variables. Significant associations with low-density lipoprotein cholesterol and apolipoprotein (Apo) B were found. Linkage disequilibrium with each other showed the haplotype-phenotype associations with triglyceride and ApoA1. This study also suggested pleiotropic associations of the CAPN3-FRMD5 diplotypes with lipid variables. As potential confounders, diastolic blood pressure (DBP) and BMI were significantly associated with lipid variables. We conclude that integrative variants, haplotypes and diplotypes of the CAPN3 rs4344713 and FRMD5 rs524908, as well as DBP and BMI are associated with serum lipid variables in the Jing and Han populations.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28332615      PMCID: PMC5378954          DOI: 10.1038/srep45119

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


The recently revised guidelines from the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) reflect an awareness that human genetic and cardiometabolic heterogeneity could be used to adjust population-based guidelines so that they are optimal for individuals1. Likewise, the summary of the 2016 conference preventive cardiovascular disease (CVD) sponsored by the ESC/EAS in Rome emphasizes that we must identify the roles of candidate genes that influence individual susceptibility to incident CVD2. Alone these lines, several loci have already been investigated for potential interaction between gene and lipid variable3. Two of these are the calpain 3 gene (CAPN3; OMIM 114240; 40-kb, 15q15.1-q21.1)4 and the FERM domain containing 5 gene (FRMD5; OMIM 616309; 15q15.3)5 that mapped to the long arm of chromosome 15 closely (Fig. 1). Their gene products play a central role in lipid metabolism67 and CVD risk89. Many genome-wide association studies (GWASs) and target single nucleotide polymorphism (SNP) studies have found significant polymorphisms of these two genes in different ethnic groups. The most frequent mutations, rs2412710 for CAPN3 and rs2929282 for FRMD5 are associated with blood lipid concentration in European Caucasian individuals1011. Our aim was to clarify the association of CAPN3 and FRMD5 with serum lipid variables in the Chinese subjects. In this study, after selection of tagging SNPs by Haploview (Broad Institute of MIT and Harvard, Cambridge, MA, USA, version 4.2), we validated the two significant SNPs, CAPN3 rs4344713 and FRMD5 rs524908, in Han Chinese in Beijing, China chosen from the 1000 Genome Project Database.
Figure 1

The positions of the CAPN3 and FRMD5 variants.

The CAPN3 contains 24 exons encoding for the 94-kDa Na+/Ca2+-dependent cysteine protease calpain-31213, which encodes several key mediators of lipid metabolism and oxidative phosphorylation14. Likewise, using a multivariate approach, a previous study reported a combination of SNPs, included SNPs in FRMD5 that explains a significant part of the variability in the postprandial chylomicron and triglyceride (TG) response15. To date, GWASs have identified hundreds of genetic clues to cardiometabolic disease. However, they are much more likely to be near a gene area closely that causes abnormal cardiometabolic traits, than a similarly sized random set of loci16. The CAPN3 rs4344713 and FRMD5 rs524908 SNPs are located so close together within a neighbor region (Fig. 1) that the linkage disequilibrium (LD) between them cannot be neglected. It was previously reported that an association analysis based on haplotype clusters increased power over single-locus test, and that another association test based on diplotype trend regression analysis outperformed other, more common association approaches1718. Therefore, a novel algorithm to combine haplotype cluster- and diplotype-based analysis is suggested. The people of the very small ethnic minority, Jing19, live in compact communities primarily on the three islands of Wanwei, Wutou and Shanxin in the county of Fangchenggang in the province of Guangxi, near the Sino-Vietnamese border. The ancestors of Jing ethnic group had immigrated from the Vietnam since the 15th century. Today, they live in nearby with predominately Han Chinese, the biggest population in China. The Jing people like to eat fish, shrimps, crabs, fish soluble and rice cakes. The daily dishes are mainly fish and shrimps, which are always made into soluble, and it is an inevitable seasoning ingredient at each meal. The typical food of the Jing people is fish soluble, which is also called silurid soluble. It is the traditional seasoning among the Jing people and is made from different kinds of small fishes which are first pickled before made into the soluble. Additionally, the Jing women like to chew betel nuts. Importantly, Jing is a relatively isolated and conservative minority not only in nature environment but also in social network. Furthermore, Jing preserves their custom of intra-ethnic marriage. Consequently, their genetic background may be less heterogeneous within the population (http://www.chinatravel.com/facts/jing-ethnic-minority.htm). Hence, considering that the CAPN3 and FRMD5 might play an important role on the etiopathogenesis of CVD, we aimed to investigate the possible association of the integrative variants, haplotypes and diplotypes of the CAPN3 rs4344713 and FRMD5 rs524908, as well as several environmental exposures with the lipid homeostasis in the Jing and Han populations.

Results

Sociodemographic and clinical characteristics

The sociodemographic and clinical characteristics of the Jing and Han participants are list in Table 1. As both groups were matched by age and gender, there were no statistically significant differences by age and gender. The mean value of body mass index (BMI) in the Jing ethnic minority was significantly higher than that in the Han population. However, the values of systolic blood pressure (SBP) and pulse pressure (PP) in the Jing group were significantly lower than those in the Han group. There were equivalent significant differences between the two ethnic groups for the social lifestyle. The percentage of light-moderate alcohol consumption was significantly higher in the Jing than in the Han individuals, while the % of severe cigarette smoking and severe alcohol consumption was significantly lower in the Jing than in the Han subjects. For serum lipid variables, the levels of total cholesterol (TC), TG and apolipoprotein (Apo) B were significantly higher and those of high-density lipoprotein cholesterol (HDL-C), ApoA1 and the ApoA1/ApoB ratio were significantly lower in the Jing than in the Han participants. However, no difference was noted in fasting serum low-density lipoprotein cholesterol (LDL-C) levels between the two ethnic groups.
Table 1

Sociodemographic and clinical characteristics of the Jing and Han populations.

CharacteristicsJing(n = 819)Han(n = 821)t(X2)P-value
Age (years)156.97 ± 12.7057.27 ± 12.861.4340.152
Gender(Male/Female)411/408413/4080.0020.961
Body mass index (kg/m2)23.42 ± 3.1822.82 ± 3.195.431 < 0.001
Systolic blood pressure (mmHg)132.02 ± 21.66137.35 ± 22.35−2.8610.004
Diastolic blood pressure (mmHg)80.78 ± 10.6481.44 ± 10.40−1.7940.073
Pulse pressure (mmHg)51.24 ± 17.2755.91 ± 21.00−2.5860.010
Cigarette smoking [n (%)]
 Nonsmoker656 (80.1)619 (75.4)  
 ≤20 Cigarette smoking/day38 (4.6)38 (4.6)  
 >20 Cigarette smoking/day125 (15.3)164 (20.0)6.3340.042
Alcohol consumption [n (%)]
 Nondrinker627 (76.6)558 (68.0)  
 ≤25 g/day95 (11.6)60 (7.3)  
 >25 g/day97 (11.8)203 (24.7)49.372 < 0.001
Total cholesterol (mmol/L)5.29 ± 0.894.99 ± 0.879.772 < 0.001
Triglyceride (mmol/L)21.51 (1.18)1.37 (1.09)−6.317 < 0.001
HDL-C (mmol/L)1.77 ± 0.541.80 ± 0.46−2.1490.032
LDL-C (mmol/L)2.87 ± 0.432.85 ± 0.431.2690.204
Apolipoprotein (Apo) A1 (g/L)1.31 ± 0.251.33 ± 0.20−2.9880.003
ApoB (g/L)1.07 ± 0.251.05 ± 0.242.5760.010
ApoA1/ApoB1.29 ± 0.381.34 ± 0.38−3.769 < 0.001

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. 1Mean ± SD determined by t-test. 2Median (interquartile range) tested by the Wilcoxon-Mann-Whitney test.

Genotypic and allelic frequencies

Regarding the analysis of gene frequencies in the CAPN3 and FRMD5, the prevalence of minor allelic, genotypic, haplotypic and diplotypic frequencies of the CAPN3 rs4344713 and FRMD5 rs524908 was significantly different between the Jing and Han populations (Table 2). We found that the rare variant or minor allele frequency (MAF) of the CAPN3 rs4344713 and FRMD5 rs524908 were significantly higher in the Jing than in the Han subjects (2.93% vs. 1.58%, P = 0.009 and 21.31% vs. 17.78%, P = 0.011; respectively). The prevalence of the CAPN3 rs4344713CC and FRMD5 rs524908CC genotypes was also significantly higher in the Jing than in the Han ethnic groups (0.25% vs. 0.12%, P = 0.038 and 5.25% vs. 3.90%, P = 0.044; respectively). Two variants in the Jing and Han populations were in the Hardy-Weinberg equilibrium (HWE, P > 0.05 for all). There was weak linkage disequilibrium (LD) between the two SNPs (D′ = 0.834, r2 = 0.075 in Jing, D′ = 0.761, r2 = 0.049 in Han, P = 0.007). Pearson correlation analysis demonstrated that the CAPN3 rs4344713 and FRMD5 rs524908 SNPs were not totally independent from each other (Fig. 2). The frequencies of haplotype and diplotype are list in Table 2. Two haplotypes (rs4344713T-rs524908A and rs4344713T-rs524908C) and two diplotypes (rs4344713TT-rs524908AA and rs4344713TT-rs524908AC) with a frequency > 5%, called “common”, were identified in the Jing and Han populations; respectively. We combined 1 haplotype (rs4344713C-rs524908C both in the Jing and Han) and 3 diplotypes (rs4344713TT-rs524908CC and rs4344713CT-rs524908AC in Han, and rs4344713CT-rs524908CC in Jing) with frequencies between 1% and 5% into one group, called “low-frequency”. The rest of haplotypes and diplotypes with frequencies less than 1% into one group, called “rare”. The haplotype of rs4344713T-rs524908A and diplotype of rs4344713TT-rs524908AA were the commonest, which accounted for over half of the % of each ethnic group.
Table 2

Distribution of variants, haplotypes and diplotypes in the Jing and Han populations[n (%)].

Type Jing (n = 819)Han (n = 821)X2P-value
AlleleCAPN3 rs4344713-MAF48 (2.93)26 (1.58)6.7470.009
FRMD5 rs524908-MAF349 (21.31)292 (17.78)6.4740.011
GenotypeCAPN3 rs4344713-TT773 (94.38)796 (96.95)  
CAPN3 rs4344713-CT44 (5.37)24 (2.93)  
CAPN3 rs4344713-CC2 (0.25)1 (0.12)6.5500.038
HWE(P-value)0.1110.075  
FRMD5 rs524908-AA513 (62.64)561 (68.33)  
FRMD5 rs524908-AC263 (32.11)228 (27.77)  
FRMD5 rs524908-CC43 (5.25)32 (3.90)6.2510.044
HWE(P-value)0.2250.150  
HaplotypeCAPN3- FRMD5 T-A1283 (78.33)1343 (81.55)  
CAPN3- FRMD5 T-C307 (18.74)273 (16.87)  
CAPN3- FRMD5 C-A6 (0.37)7 (0.67)  
CAPN3- FRMD5 C-C42 (2.56)19 (0.91)11.9750.001
DiplotypeCAPN3- FRMD5 TT-AA509 (62.15)556 (67.72)  
CAPN3- FRMD5 TT-AC261 (31.87)215 (26.19)  
CAPN3- FRMD5 TT-CC3 (0.37)25 (3.05)  
CAPN3- FRMD5 CT-AA2 (0.24)4 (0.49)  
CAPN3- FRMD5 CT-AC2 (0.24)13 (1.58)  
CAPN3- FRMD5 CT-CC40 (4.89)7 (0.85)  
CAPN3- FRMD5 CC-AA2 (0.24)1 (0.12)  
CAPN3- FRMD5 CC-AC0 (0)0 (0)  
CAPN3- FRMD5 CC-CC0 (0)0 (0)56.040 < 0.001

MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; Haplotypes and diplotypes were in the order of CAPN3 rs4344713 and FRMD5 rs524908.

Figure 2

Inter-locus correlation of the CAPN3 and FRMD5 in the Jing and Han ethnic groups.

Genotypes and serum lipid phenotypes

As shown in Table 3, the levels of LDL-C, ApoB and the ratio of ApoA1 to ApoB in the Jing population were significantly different between the CAPN3 rs4344713TT and CT/CC or among the FRMD5 rs524908AA, AC and CC genotypes after the Bonferroni correction (P ≤ 0.022). There was no association of the two SNPs and serum lipid phenotypes in the Han population.
Table 3

Associations of the CAPN3 and FRMD5 variants and serum lipid phenotypes in the Jing and Han populations.

Allele/GenotypeTC (mmol/L)1TG (mmol/L)2HDL-C (mmol/L)LDL-C (mmol/L)ApoA1 (g/L)ApoB (g/L)ApoA1/ApoB
CAPN3 rs4344713 T > C
Jing
 TT5.29 ± 0.901.50 (1.17)1.81 ± 0.462.84 ± 0.431.31 ± 0.251.07 ± 0.251.29 ± 0.38
 CT/CC5.34 ± 0.781.59 (1.28)1.77 ± 0.422.95 ± 0.421.27 ± 0.231.11 ± 0.261.21 ± 0.42
F0.222−1.5172.5645.7633.0215.2456.510
P0.6370.1290.1100.0160.0820.0220.011
Han
 TT4.98 ± 0.791.36 (1.09)1.86 ± 0.472.86 ± 0.431.33 ± 0.201.04 ± 0.241.34 ± 0.38
 CT/CC4.99 ± 0.881.50 (1.17)1.76 ± 0.542.90 ± 0.431.33 ± 0.191.07 ± 0.241.29 ± 0.32
F0.007−1.9180.4290.4030.0300.5420.861
P0.9350.0550.5130.5260.8620.4620.354
FRMD5 rs524908 A > C
Jing
 AA5.28 ± 0.911.50 (1.17)1.81 ± 0.482.82 ± 0.461.32 ± 0.261.06 ± 0.251.31 ± 0.38
 AC5.30 ± 0.871.54 (1.24)1.80 ± 0.442.85 ± 0.421.28 ± 0.211.08 ± 0.251.25 ± 0.37
 CC5.36 ± 0.791.59 (1.28)1.77 ± 0.412.97 ± 0.411.28 ± 0.231.13 ± 0.261.21 ± 0.43
F0.371−1.6791.1804.5843.6745.8477.701
P0.6900.0930.3070.0100.0260.0030.000
Han
 AA4.87 ± 0.801.36 (1.07)1.81 ± 0.512.86 ± 0.421.33 ± 0.211.04 ± 0.231.34 ± 0.39
 AC4.98 ± 0.841.46 (1.12)1.75 ± 0.572.87 ± 0.431.33 ± 0.201.05 ± 0.241.34 ± 0.36
 CC4.99 ± 0.891.49 (1.13)1.70 ± 0.392.89 ± 0.441.27 ± 0.181.09 ± 0.211.21 ± 0.31
F1.400−1.5250.5980.0822.2820.2942.157
P0.2470.1270.5500.9220.1020.7460.116

TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B. 1Mean ± SD determined by the ANCOVA. 2Median (interquartile range) tested by the Wilcoxon-Mann-Whitney test or Kruskal-Wallis test. A P-value less than 0.025 was considered statistically significant after the Bonferroni correction.

Haplotypes and serum lipid phenotypes

After the Bonferroni correction, the levels of TG (rs4344713T-rs524908A and rs4344713C-rs524908A), ApoA1 (rs4344713T-rs524908A, rs4344713T-rs524908C and rs4344713C-rs524908A), ApoB (rs4344713T-rs524908A and rs4344713T-rs524908C) and the ApoA1/ApoB ratio (rs4344713T-rs524908A and rs4344713T-rs524908C) in Jing; and TG (rs4344713C-rs524908A) in Han were significantly different between the haplotype carriers and non-carriers (P ≤ 0.019, Table 4). The association analysis based on haplotype cluster increased power over single-locus tests.
Table 4

Associations of the haplotypes and serum lipid phenotypes in the Jing and Han populations.

HaplotypeGroupTC (mmol/L)1TG (mmol/L)2HDL-C (mmol/L)LDL-C (mmol/L)ApoA1 (g/L)ApoB (g/L)ApoA1/ApoB
T-AJing
Carrier5.28 ± 0.911.50 (1.17)1.81 ± 0.472.85 ± 0.431.31 ± 0.251.06 ± 0.251.30 ± 0.38
Non-carrier5.31 ± 0.841.55 (1.24)1.79 ± 0.432.86 ± 0.451.28 ± 0.221.09 ± 0.251.24 ± 0.38
F0.558−2.6522.1470.7359.37411.69218.321
P0.4550.0080.1430.3910.0020.0010.000
Han
Carrier4.99 ± 0.881.36 (1.08)1.76 ± 0.562.87 ± 0.431.33 ± 0.201.04 ± 0.241.34 ± 0.38
Non-carrier4.96 ± 0.831.46 (1.12)1.79 ± 0.492.87 ± 0.421.32 ± 0.201.05 ± 0.231.32 ± 0.35
F1.205−2.2120.0070.0090.7790.7762.992
P0.2720.0270.9360.9260.3780.3780.084
T-CJing
Carrier5.31 ± 0.851.54 (1.24)1.79 ± 0.432.85 ± 0.461.28 ± 0.221.09 ± 0.251.24 ± 0.38
Non-carrier5.29 ± 0.901.51 (1.17)1.81 ± 0.472.85 ± 0.431.31 ± 0.251.06 ± 0.251.30 ± 0.38
F0.399−2.0160.6440.0125.7836.88011.252
P0.5280.0440.4220.9130.0160.0090.001
Han
Carrier4.96 ± 0.841.46 (1.12)1.78 ± 0.492.87 ± 0.421.32 ± 0.201.05 ± 0.231.32 ± 0.36
Non-carrier4.99 ± 0.881.37 (1.09)1.76 ± 0.552.87 ± 0.431.33 ± 0.201.04 ± 0.241.34 ± 0.38
F1.321−1.5200.0200.0230.7750.3832.109
P0.2500.1280.8880.8810.3790.5360.147
C-AJing
Carrier5.36 ± 0.582.01 (1.77)1.44 ± 0.382.97 ± 0.281.13 ± 0.161.16 ± 0.200.99 ± 0.18
Non-carrier5.29 ± 0.891.51 (1.17)1.80 ± 0.462.85 ± 0.441.31 ± 0.251.07 ± 0.251.29 ± 0.38
F0.057−3.2623.6480.7525.5310.4634.548
P0.8110.0010.0560.3860.0190.4960.033
Han
Carrier5.23 ± 0.702.02 (1.77)1.76 ± 0.513.04 ± 0.311.34 ± 0.261.21 ± 0.231.15 ± 0.42
Non-carrier4.99 ± 0.871.37 (1.09)1.77 ± 0.542.87 ± 0.431.33 ± 0.201.05 ± 0.241.34 ± 0.38
F0.102−3.1790.0070.6250.5263.8461.130
P0.7490.0010.9320.4290.4680.0500.288
C-CJing
Carrier5.32 ± 0.801.55 (1.22)1.80 ± 0.402.95 ± 0.431.28 ± 0.231.11 ± 0.261.23 ± 0.43
Non-carrier5.29 ± 0.891.51 (1.18)1.80 ± 0.462.85 ± 0.431.31 ± 0.251.07 ± 0.251.29 ± 0.38
F0.090−0.6911.2654.8921.3274.8284.282
P0.7640.4900.2610.0270.2490.0280.039
Han
Carrier4.93 ± 0.781.48 (1.16)1.87 ± 0.462.88 ± 0.441.33 ± 0.181.05 ± 0.241.31 ± 0.29
Non-carrier4.99 ± 0.871.37 (1.09)1.76 ± 0.542.87 ± 0.431.33 ± 0.201.05 ± 0.241.34 ± 0.38
F0.015−0.9580.5050.1510.1910.0010.332
P0.9010.3380.4770.6980.6620.9760.564

TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B. 1Mean ± SD determined by the ANCOVA. 2Median (interquartile range) tested by the Wilcoxon-Mann-Whitney test. A P-value less than 0.025 was considered statistically significant after the Bonferroni correction.

Diplotypes and serum lipid phenotypes

As shown in Table 5, the levels of TG (rs4344713TT-rs524908AA, rs4344713TT-rs524908CC and rs4344713CT/CC-rs524908AA), HDL-C (rs4344713TT-rs524908CC), LDL-C (rs4344713CT/CC-rs524908CC), ApoA1 (rs4344713TT-rs524908AA), ApoB (rs4344713TT-rs524908AA) and ApoA1/ApoB (rs4344713TT-rs524908AA, rs4344713TT-rs524908AC and rs4344713TT-rs524908CC) in Jing; and TG (rs4344713CT/CC-rs524908AA) and ApoA1 (rs4344713TT-rs524908CC) in Han were significantly different between the diplotype carriers and non-carriers after the Bonferroni correction (P ≤ 0.023). The association test based on diplotype outperformed other more common single variant association approaches.
Table 5

Associations of the diplotypes and serum lipid phenotypes in the Jing and Han populations.

DiplotypeGroupTC (mmol/L)1TG (mmol/L)2HDL-C (mmol/L)LDL-C (mmol/L)ApoA1 (g/L)ApoB (g/L)ApoA1/ApoB
TT-AAJing
Carrier5.28 ± 0.921.50 (1.17)1.81 ± 0.482.85 ± 0.421.32 ± 0.261.06 ± 0.251.31 ± 0.38
Non-carrier5.31 ± 0.851.55 (1.24)1.79 ± 0.432.85 ± 0.461.28 ± 0.221.09 ± 0.251.24 ± 0.38
F0.315−2.3420.9540.0638.5917.76614.934
P0.5750.0190.3290.8010.0030.0050.000
Han
Carrier4.99 ± 0.891.36 (1.07)1.75 ± 0.572.86 ± 0.431.33 ± 0.201.04 ± 0.241.34 ± 0.39
Non-carrier4.97 ± 0.841.46 (1.12)1.80 ± 0.502.87 ± 0.421.33 ± 0.201.05 ± 0.231.33 ± 0.36
F0.339−2.1300.2140.0620.0220.4681.332
P0.5600.0330.6440.8030.8820.4940.249
TT-ACJing
Carrier5.30 ± 0.861.54 (1.23)1.80 ± 0.442.82 ± 0.461.28 ± 0.221.08 ± 0.251.25 ± 0.37
Non-carrier5.29 ± 0.911.51 (1.17)1.81 ± 0.472.86 ± 0.421.32 ± 0.261.06 ± 0.251.30 ± 0.39
F0.042−1.2570.0142.6434.0112.1155.903
P0.8370.2090.9060.1040.0450.1460.015
Han
Carrier4.98 ± 0.851.46 (1.10)1.81 ± 0.512.86 ± 0.421.34 ± 0.201.04 ± 0.231.35 ± 0.36
Non-carrier4.99 ± 0.881.37 (1.09)1.75 ± 0.562.87 ± 0.431.32 ± 0.201.05 ± 0.241.33 ± 0.38
F0.025−0.7380.3620.0030.7580.0110.000
P0.8730.4610.5470.9590.3840.9170.984
TT-CCJing
Carrier5.55 ± 0.932.00 (1.84)1.41 ± 0.243.05 ± 0.391.20 ± 0.111.28 ± 0.140.95 ± 0.16
Non-carrier5.29 ± 0.891.51 (1.17)1.81 ± 0.462.85 ± 0.431.31 ± 0.251.07 ± 0.251.29 ± 0.38
F0.978−2.9355.4601.5221.6974.6315.013
P0.3230.0030.0200.2180.1930.0320.025
Han
Carrier4.92 ± 0.821.49 (1.19)1.68 ± 0.412.90 ± 0.451.26 ± 0.181.09 ± 0.211.20 ± 0.32
Non-carrier4.99 ± 0.871.37 (1.09)1.77 ± 0.552.87 ± 0.431.33 ± 0.201.04 ± 0.241.34 ± 0.38
F1.419−1.7560.8500.0185.1810.5544.185
P0.2340.0790.3570.8930.0230.4570.041
CT/CC-AAJing
Carrier5.47 ± 0.612.01 (1.70)1.47 ± 0.442.99 ± 0.311.14 ± 0.171.16 ± 0.211.01 ± 0.20
Non-carrier5.29 ± 0.891.51 (1.17)1.81 ± 0.462.85 ± 0.441.31 ± 0.251.07 ± 0.251.29 ± 0.38
F0.316−2.6252.5620.6873.7740.2842.952
P0.5740.0090.1100.4070.0520.5940.086
Han
Carrier5.26 ± 0.731.97 (1.71)1.80 ± 0.523.05 ± 0.331.36 ± 0.271.20 ± 0.231.18 ± 0.43
Non-carrier4.98 ± 0.871.36 (1.09)1.76 ± 0.542.87 ± 0.431.33 ± 0.201.04 ± 0.241.34 ± 0.38
F0.183−2.9380.0050.7040.7013.2370.822
P0.6690.0030.9420.4010.4030.0720.365
CT/CC-ACJing
Carrier5.00 ± 1.161.63 (1.56)1.60 ± 0.492.68 ± 0.621.24 ± 0.191.10 ± 0.211.15 ± 0.22
Non-carrier5.29 ± 0.891.51 (1.18)1.80 ± 0.462.85 ± 0.431.31 ± 0.251.07 ± 0.251.29 ± 0.38
F0.992−0.6782.3020.5470.5710.0470.793
P0.3190.4970.1290.4600.4500.8290.373
Han
Carrier5.00 ± 0.801.49 (1.20)1.87 ± 0.492.89 ± 0.461.32 ± 0.191.05 ± 0.251.32 ± 0.31
Non-carrier4.99 ± 0.871.37 (1.09)1.76 ± 0.542.87 ± 0.431.33 ± 0.201.05 ± 0.241.34 ± 0.38
F0.319−1.7470.4570.3750.3950.0000.288
P0.5720.0810.4990.5400.5300.9830.592
CT/CC-CCJing
Carrier5.34 ± 0.781.51 (1.17)1.81 ± 0.402.96 ± 0.421.29 ± 0.231.11 ± 0.271.24 ± 0.44
Non-carrier5.29 ± 0.901.52 (1.18)1.80 ± 0.462.84 ± 0.441.31 ± 0.251.07 ± 0.251.29 ± 0.38
F0.295−0.5580.6626.0951.0384.9743.763
P0.5870.5770.4160.0140.3080.0260.053
Han
Carrier4.52 ± 0.611.04 (0.93)1.85 ± 0.232.81 ± 0.361.36 ± 0.161.08 ± 0.201.30 ± 0.24
Non-carrier4.99 ± 0.871.37 (1.10)1.76 ± 0.542.87 ± 0.431.33 ± 0.201.05 ± 0.241.34 ± 0.38
F2.334−1.9550.0180.3420.0070.0150.094
P0.1270.0510.8930.5590.9330.9030.760

TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoA1/ApoB, the ratio of apolipoprotein A1 to apolipoprotein B. 1Mean ± SD determined by the ANCOVA. 2Median (interquartile range) tested by the Wilcoxon-Mann-Whitney test. A P-value less than 0.025 was considered statistically significant after the Bonferroni correction.

Genotypes, haplotypes and diplotypes and serum lipid phenotypes

Table 6 shows the magnitude and direction of correlation between serum lipid levels and integrative genotypes, haplotypes and diplotypes in the two populations. Many of the examining variants showed significant correlation with serum lipid levels in multiple linear regression analysis; although, these variants did not show significant association with serum lipid levels in the analysis of covariance (ANCOVA). Furthermore, the significantly differences in the LDL-C level change per increment of CAPN3 genotype was Beta/Se 0.059/0.046 (P = 0.016), as well as HDL-C, ApoA1, ApoB levels and the ApoA1/ApoB ratio change per increment of FRMD5 genotype were −0.359/0.150 (P = 0.017); −0.063/0.010 (P = 0.009); 0.079/0.010 (P = 0.001) and −0.096/0.015 (P < 0.001) in the Jing participants, respectively. In addition, the significantly differently in the HDL-C change per increment of their haplotype was Beta/Se 0.535/0.233 (P = 0.023), as well as marginal significantly differently in the ApoA1 change per increment of their haplotype was Beta/Se 0.159/0.075 (P = 0.033) and the ApoA1/ApoB ratio change per increment of their diplotype was Beta/Se 0.414/0.201 (P = 0.040). However, we did not obtain any significant association (having taken correction for multiple comparisons into account) with any of these biomarkers in the Han population of this ethnic-stratified analysis. The novel algorithm to combine haplotype cluster- and diplotype-based analyses is useful for identifying more precise and distinct signals over single-locus tests.
Table 6

Association of the variants, haplotypes and diplotypes of the CAPN3 and FRMD5 and serum lipid variables.

Lipid variableGeneTypeBetaStd.errorChi-squareP-value
Jing
HDL-CFRMD5Genotype−0.3590.1505.7270.017
HDL-CCAPN3-FRMD5Diplotype0.5350.2355.1910.023
LDL-CCAPN3Genotype0.0590.0462.4100.016
ApoA1FRMD5Genotype−0.0630.010−2.6280.009
ApoA1CAPN3-FRMD5Haplotype0.1590.0754.5550.033
ApoBFRMD5Genotype0.0790.0103.3010.001
ApoA1/ApoBFRMD5Genotype−0.0960.015−4.0700.000
ApoA1/ApoBCAPN3-FRMD5Diplotype0.4140.2014.2360.040

There was no significantly association in the Han population.

Relative factors for serum lipid phenotypic parameters

As shown in Fig. 3, Pearson correlation analysis showed that the integrative variants, haplotype and diplotype evidence connects the CAPN3 rs4344713 and FRMD5 rs524908 to lipid variables. Several environmental exposures such as age, gender, cigarette smoking, alcohol consumption and traditional cardiovascular risk factors such as BMI and blood pressure levels were also correlated with serum lipid phenotypic parameters of both ethnic groups.
Figure 3

Correlation between environmental exposures and serum lipid variables, as well as the candidate locus.

Discussion

In the present study, we first confirmed that (i) not only the CAPN3 rs4344713 CT/CC genotype and the FRMD5 rs524908 CC genotype, but also the rs4344713C-rs524908C haplotype and the rs4344713CT/CC-rs524908CC diplotype were good proxies for higher serum LDL-C and ApoB levels in the Jing but not in the Han populations; (ii) the rs4344713T-rs524908A, rs4344713T-rs524908C and rs4344713C-rs524908A haplotypes were associated with TG and ApoA1 in the Jing particiapnts, as well as associated with TG in the Han subjects; and (iii) the results of our study also suggest a pleiotropic association of the CAPN3-FRMD5 diplotypes with lipid variables in the both Jing and Han populations. In summary, the data presented here suggest differences in lipid variables between the two populations might partially attribute to CAPN3 rs4344713 and FRMD5 rs524908 variants, while this heterogeneity needs to be confirmed in other populations in order to better assess its important. Moreover, to combine haplotype cluster- and diplotype-based analyses is useful for identifying more precise and distinct signals over single-locus tests. A couples of years ago, Schunkert et al.8 found that the individuals with CAPN3 rs24212710G allele were positively associated with plasma TG levels (n = 153,909, P = 1.7 × 10−11) and increased the risk of CVD (n = 79,267, P = 5.3 × 10−3) in the European population. Likewise, in the same European population’s large-scale association study, the FRMD5 rs2929282A allele carriers had higher TG levels (n = 83,616, P = 2 × 10−9) and risk of CVD (n = 81,446, P = 2.8 × 10−3) than the rs2929282A allele non-carriers. However, no association was seen between the FRMD5 rs2929282 and BMI (n = 122,284, P = 1.1 × 10−2). In the present study, we found that the CAPN3 rs4344713CT/CC genotype and the FRMD5 rs524908CC genotype were more frequent in the Jing than in the Han populations. The subjects with the CAPN3 rs4344713CT/CC genotype and the FRMD5 rs524908CC genotype tend to have higher serum LDL-C and ApoB levels in the Jing ethnic minority. However, no such association was observed in the Han population. The reason for this discrepancy among these studies is not fully understood. It might result from the difference in the genetic background, ethnic LD pattern and/or environmental factors. On inter-locus interaction analyses, we confirmed the CAPN3 rs4344713 T > C variant in low LD with the FRMD5 rs524908 A > C. At least, they are not statistically independent. In single locus analysis, only LDL-C, ApoB levels and the ApoA1/ApoB ratio were associated with the detected variants. However, in haplotype cluster- and diplotype-based analyses, significant associations with pleiotropic lipid variables were found in the CAPN3-FRMD5 haplotype and diplotype models. These findings indicate that a potential gene-gene interaction might exist between the CAPN3 rs4344713 and FRMD5 rs524908 variants. Unfortunately, no previous study has investigated the inter-locus interaction between these variants, and therefore we cannot make comparisons with our results. Although, a statistically significant variant-, haplotype- and diplotype-based association was noted in this study, the biological mechanism underlying these genes and their interactions is still yet to be defined. When assessing the association of several environmental exposures with lipid variables, we showed that diastolic blood pressure (DBP) and BMI were strongly associated with serum lipid levels in the both Jing and Han populations. A novel extension to the phenome-wide association study (pheWAS) approach20, using Bonferroni corrections, permutation testing and estimates of the false discovery rate to consider the strength of results given the number of tests performed demonstrated strongly associated outcomes included DBP and BMI with lipid profiles. They also found novel evidence of effects of BMI on a global self-worth score. Previous studies have reported not only higher DBP21 but also both overweight and obesity2223 are associated with an increased risk of CVD death and all-cause mortality. Furthermore, achieving and maintaining a healthy weight has a favorable effect on metabolic risk factors (blood pressure, lipids) and low CVD risk. Whatever, we considered these variables as potential confounders and performed a crude statistical analysis and a multivariate analysis adjusting for these variables. CAPN3 encodes CAPN3, a heterodimer consisting of a large and a small subunit, is a major intracellular protease24, although its function has not been well established. Mutations in this gene25 are associated with lipid metabolism. Alternate promoters and alternative splicing result in multiple transcript variants encoding different isoforms and some variants are ubiquitously expressed. Likewise, FRMD5 encodes FERM-containing protein FRMD5, a p120-catenin interacting protein, regulates lipid metabolic progression26. Our study is the first one carried out in a south Chinese population and the first to find a significant association between this integrative variants, haplotype and diplotypes of the CAPN3 and FRMD5 with lipid variables. After adjustment for several potential confounders, this association remained significant. Sampling bias cannot be ignored. In our statistics, the sample is collected in previous specimen library that some members of the intended population are less likely to be included than others. It results in a biased sample, a non-random sample27 of a population (non-human or human factors) in which all individuals, or instances, were not equally likely to have been selected28. If this is not accounted for, results can be erroneously attributed to the phenomenon under study rather than to the method of sampling. As an ascertainment bias sometimes classified as the inevitable type of bias. Our analyses benefited from a strong a priori hypothesis, a good sample size for a sub-ethnic study, and a healthy population, making generalizations to other samples less problematic than with clinical samples. However, there are some limitations: first, the association in the present study should be tested in more racially diverse populations. Second, many of our conclusions regarding associations did not survive the FDR correction for multiple testing, so should be considered preliminary. Third, it is not clear why some variants in LD with each other did not show the same genotype-phenotype associations. Moreover, observational analyses may not provide robust evidence of causality, as they are susceptible to confounding, reverse causation and measurement error. The last but not the least, the selected variants may not the accurate and precise hits because tagging SNPs selection bias is inevitable. In conclusion, integrative variants, haplotypes and diplotypes of the CAPN3 rs4344713 and FRMD5 rs524908, as well as DBP and BMI associated with lipid variables in the Jing and Han populations. These associations may contribute to future novel dyslipidemia diagnosis biomarkers and pharmacogenomics therapy targets.

Materials and Methods

Ethics statement

Protocols in the present study have approval from the Ethics Committee of the First Affiliated Hospital, Guangxi Medical University (No: Lunshen-2011-KY-Guoji-001; Mar. 7, 2011). Subjects from contributing populations gave written informed consent to participate in epidemiologic investigation, biochemical measurement and genetic analysis. This study was carried out following the rules of the Declaration of Helsinki of 1975 (http://www.wma.net/en/30publications/10policies/b3/), revised in 2008.

Subjects

The Jing participants in the current study were mainly recruited from three islands: Wanwei, Wutou and Shanxin. Eligibility criteria were (1) ≥ 18 years of age; (2) willing to participate in epidemiologic investigation, biochemical measurement and genetic analysis of this project; (3) their birthplaces and those of their parents, grandparents, and great-grandparents clustered in the abovementioned three islands; (4) their ethnicities and those of their parents, grandparents, and great-grandparents were the same one (Jing); (5) myocardial enzymes, aspartate aminotransferase, alanine aminotransferase, and creatinine results within normal range; and (6) normal electrocardiography (ECG) results. Exclusion criteria were (1) with history of coronary artery disease, stroke, diabetes, hyper- or hypo-thyroids, and chronic hepatic and renal disease; (2) use of lipid lower drugs, including prescription, over-the-counter and nutraceuticals; and (3) other medications known to affect lipid profiles, such as insulin use. After granting informed consent, participants underwent a baseline-screening visit and a fasting blood draw. A total of 1800 Jing subjects were asked to participate in the study and 1674 Jing subjects actually participated17. The response rate was 93% in Jing. A total of 52 persons (3.1%) with a history and/or evidence of other diseases were excluded from the Jing samples. The sampling of the Han population was also done in the same place, by the same method. Importantly, the participants of this study were randomly selected from our previous stratified randomized samples, just included 818 Jing subjects and 822 Han participants.

Biochemical analyses

Protocols for measuring lipid variables have been previously described29. All lipid variables were measured in our Clinical Science Experiment Center. The levels of fasting serum TC, TG, HDL-C and LDL-C in the samples were determined by enzymatic methods with commercially available kits. Fasting serum ApoA1 and ApoB levels were assessed by the immuneturbidimetric immunoassay, respectively.

Tagging SNPs selection

We selected two SNPs in the CAPN3/FRMD5 with the following steps: (i) CAPN3 gene clusters, which were selected from previous GWAS associated with lipid-metabolism. FRMD5 gene clusters are found to be close to CAPN3 gene clusters and associated with serum lipid level especially TG. (ii) Tagging SNPs, which were established by Haploview (Broad Institute of MIT and Harvard, USA, version 4.2) and functional SNPs predicted to lead to serum lipid changes from current version of online resource (1000 Genome Project Database). (iii) CAPN3 rs2412710 and FRMD5 rs2929282, which were selected by the block-based approach. This strategy is enable by the correlations between tagging SNPs as manifested as LD. Although classic is not goal of tagging SNP selection, innovative tagging SNPs selection bias is inevitable.

Variant genotyping

Genomic DNA was extracted from leucocytes of venous blood using the phenol-chloroform method. Genotyping was performed in each population separately with PCR and Sanger sequencing. The PCR products of the samples were sequenced with a sequencer ABI Prism 3100 Genetic Analyzer (Applied Biosystems, International Equipment Trading Ltd., Vernon Hills, IL, USA) in Shanghai Sangon Biological Engineering Technology & Services Co. Ltd., Shanghai, China30.

Statistical analyses

The statistical analyses were performed with the statistical software SPSS 21.0 (SPSS Inc., Chicago, IL, USA). Quantitative variables were presented as the mean ± SD for those, that are normally distributed, whereas the medians and interquartile ranges for TG, which is not normally distributed. General characteristics between the two groups were compared by the ANCOVA. The distributions of the genotype, allele, haplotype and diplotype between the two groups were analyzed by the chi-squared test; The HWE, Pair-wise LD, frequencies of haplotype and diplotype interaction comprising the variants were calculated using Haploview (version 4.2; Broad Institute of MIT and Harvard) and PLINK (version 1.9; Broad Institute of MIT and Harvard) software. The association of the genotypes, haplotypes and diplotypes with lipid variables was tested by the Univariant. As 2 loci are not totally independent from each other, we determined these variants represented 1.86 independent loci using Matrix Spectral Decomposition. For all analyses, a Bonferroni test adjusted P-value less than 0.025 was considered statistically significant, and the P-value between 0.025–0.05 was considered marginal statistically significant. Generalized linear models were used to assess the association of the genotypes (common homozygote genotype = 1, heterozygote genotype = 2, rare homozygote genotype = 3), alleles (the minor allele non-carrier = 1, the minor allele carrier = 2), haplotypes (the haplotype non-carrier = 1, the haplotype carrier = 2) and diplotypes (the diplotype non-carrier = 1, the diplotype carrier = 2) with lipid variables. The model of age, gender, BMI, waist circumference, systolic blood pressure, DBP, pulse pressure, cigarette smoking, alcohol consumption and fasting blood glucose level were adjusted for the statistical analysis. The heart-map of inter-locus models was measured by R software (version 3.3.0).

Additional Information

How to cite this article: Guo, T. et al. Integrative variants, haplotypes and diplotypes of the CAPN3 and FRMD5 genes and several environmental exposures associate with serum lipid variables. Sci. Rep. 7, 45119; doi: 10.1038/srep45119 (2017). Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
  30 in total

1.  Astrophysics: is a doomsday catastrophe likely?

Authors:  Max Tegmark; Nick Bostrom
Journal:  Nature       Date:  2005-12-08       Impact factor: 49.962

2.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors:  Alberico L Catapano; Ian Graham; Guy De Backer; Olov Wiklund; M John Chapman; Heinz Drexel; Arno W Hoes; Catriona S Jennings; Ulf Landmesser; Terje R Pedersen; Željko Reiner; Gabriele Riccardi; Marja-Riita Taskinen; Lale Tokgozoglu; W M Monique Verschuren; Charalambos Vlachopoulos; David A Wood; Jose Luis Zamorano
Journal:  Atherosclerosis       Date:  2016-09-01       Impact factor: 5.162

3.  Body-mass index and mortality among 1.46 million white adults.

Authors:  Amy Berrington de Gonzalez; Patricia Hartge; James R Cerhan; Alan J Flint; Lindsay Hannan; Robert J MacInnis; Steven C Moore; Geoffrey S Tobias; Hoda Anton-Culver; Laura Beane Freeman; W Lawrence Beeson; Sandra L Clipp; Dallas R English; Aaron R Folsom; D Michal Freedman; Graham Giles; Niclas Hakansson; Katherine D Henderson; Judith Hoffman-Bolton; Jane A Hoppin; Karen L Koenig; I-Min Lee; Martha S Linet; Yikyung Park; Gaia Pocobelli; Arthur Schatzkin; Howard D Sesso; Elisabete Weiderpass; Bradley J Willcox; Alicja Wolk; Anne Zeleniuch-Jacquotte; Walter C Willett; Michael J Thun
Journal:  N Engl J Med       Date:  2010-12-02       Impact factor: 91.245

4.  FERM-containing protein FRMD5 is a p120-catenin interacting protein that regulates tumor progression.

Authors:  Tao Wang; Xuelian Pei; Jun Zhan; Jinxia Hu; Yu Yu; Hongquan Zhang
Journal:  FEBS Lett       Date:  2012-07-27       Impact factor: 4.124

5.  2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors:  Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno
Journal:  Eur Heart J       Date:  2016-05-23       Impact factor: 29.983

6.  Failure to up-regulate transcription of genes necessary for muscle adaptation underlies limb girdle muscular dystrophy 2A (calpainopathy).

Authors:  Irina Kramerova; Natalia Ermolova; Ascia Eskin; Andrea Hevener; Oswald Quehenberger; Aaron M Armando; Ronald Haller; Nadine Romain; Stanley F Nelson; Melissa J Spencer
Journal:  Hum Mol Genet       Date:  2016-03-22       Impact factor: 6.150

7.  Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.

Authors:  Heribert Schunkert; Inke R König; Sekar Kathiresan; Muredach P Reilly; Themistocles L Assimes; Hilma Holm; Michael Preuss; Alexandre F R Stewart; Maja Barbalic; Christian Gieger; Devin Absher; Zouhair Aherrahrou; Hooman Allayee; David Altshuler; Sonia S Anand; Karl Andersen; Jeffrey L Anderson; Diego Ardissino; Stephen G Ball; Anthony J Balmforth; Timothy A Barnes; Diane M Becker; Lewis C Becker; Klaus Berger; Joshua C Bis; S Matthijs Boekholdt; Eric Boerwinkle; Peter S Braund; Morris J Brown; Mary Susan Burnett; Ian Buysschaert; John F Carlquist; Li Chen; Sven Cichon; Veryan Codd; Robert W Davies; George Dedoussis; Abbas Dehghan; Serkalem Demissie; Joseph M Devaney; Patrick Diemert; Ron Do; Angela Doering; Sandra Eifert; Nour Eddine El Mokhtari; Stephen G Ellis; Roberto Elosua; James C Engert; Stephen E Epstein; Ulf de Faire; Marcus Fischer; Aaron R Folsom; Jennifer Freyer; Bruna Gigante; Domenico Girelli; Solveig Gretarsdottir; Vilmundur Gudnason; Jeffrey R Gulcher; Eran Halperin; Naomi Hammond; Stanley L Hazen; Albert Hofman; Benjamin D Horne; Thomas Illig; Carlos Iribarren; Gregory T Jones; J Wouter Jukema; Michael A Kaiser; Lee M Kaplan; John J P Kastelein; Kay-Tee Khaw; Joshua W Knowles; Genovefa Kolovou; Augustine Kong; Reijo Laaksonen; Diether Lambrechts; Karin Leander; Guillaume Lettre; Mingyao Li; Wolfgang Lieb; Christina Loley; Andrew J Lotery; Pier M Mannucci; Seraya Maouche; Nicola Martinelli; Pascal P McKeown; Christa Meisinger; Thomas Meitinger; Olle Melander; Pier Angelica Merlini; Vincent Mooser; Thomas Morgan; Thomas W Mühleisen; Joseph B Muhlestein; Thomas Münzel; Kiran Musunuru; Janja Nahrstaedt; Christopher P Nelson; Markus M Nöthen; Oliviero Olivieri; Riyaz S Patel; Chris C Patterson; Annette Peters; Flora Peyvandi; Liming Qu; Arshed A Quyyumi; Daniel J Rader; Loukianos S Rallidis; Catherine Rice; Frits R Rosendaal; Diana Rubin; Veikko Salomaa; M Lourdes Sampietro; Manj S Sandhu; Eric Schadt; Arne Schäfer; Arne Schillert; Stefan Schreiber; Jürgen Schrezenmeir; Stephen M Schwartz; David S Siscovick; Mohan Sivananthan; Suthesh Sivapalaratnam; Albert Smith; Tamara B Smith; Jaapjan D Snoep; Nicole Soranzo; John A Spertus; Klaus Stark; Kathy Stirrups; Monika Stoll; W H Wilson Tang; Stephanie Tennstedt; Gudmundur Thorgeirsson; Gudmar Thorleifsson; Maciej Tomaszewski; Andre G Uitterlinden; Andre M van Rij; Benjamin F Voight; Nick J Wareham; George A Wells; H-Erich Wichmann; Philipp S Wild; Christina Willenborg; Jaqueline C M Witteman; Benjamin J Wright; Shu Ye; Tanja Zeller; Andreas Ziegler; Francois Cambien; Alison H Goodall; L Adrienne Cupples; Thomas Quertermous; Winfried März; Christian Hengstenberg; Stefan Blankenberg; Willem H Ouwehand; Alistair S Hall; Panos Deloukas; John R Thompson; Kari Stefansson; Robert Roberts; Unnur Thorsteinsdottir; Christopher J O'Donnell; Ruth McPherson; Jeanette Erdmann; Nilesh J Samani
Journal:  Nat Genet       Date:  2011-03-06       Impact factor: 38.330

8.  Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease.

Authors:  Anna Helgadottir; Solveig Gretarsdottir; Gudmar Thorleifsson; Eirikur Hjartarson; Asgeir Sigurdsson; Audur Magnusdottir; Aslaug Jonasdottir; Helgi Kristjansson; Patrick Sulem; Asmundur Oddsson; Gardar Sveinbjornsson; Valgerdur Steinthorsdottir; Thorunn Rafnar; Gisli Masson; Ingileif Jonsdottir; Isleifur Olafsson; Gudmundur I Eyjolfsson; Olof Sigurdardottir; Maryam S Daneshpour; Davood Khalili; Fereidoun Azizi; Dorine W Swinkels; Lambertus Kiemeney; Arshed A Quyyumi; Allan I Levey; Riyaz S Patel; Salim S Hayek; Ingibjorg J Gudmundsdottir; Gudmundur Thorgeirsson; Unnur Thorsteinsdottir; Daniel F Gudbjartsson; Hilma Holm; Kari Stefansson
Journal:  Nat Genet       Date:  2016-05-02       Impact factor: 41.307

9.  Clinical and Pathological Heterogeneity of Korean Patients with CAPN3 Mutations.

Authors:  Hyung Jun Park; Hoon Jang; Jung Hwan Lee; Ha Young Shin; Sung Rae Cho; Kee Duk Park; Duhee Bang; Min Goo Lee; Seung Min Kim; Ji Hyun Lee; Young Chul Choi
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

10.  Discovery and refinement of loci associated with lipid levels.

Authors:  Cristen J Willer; Ellen M Schmidt; Sebanti Sengupta; Michael Boehnke; Panos Deloukas; Sekar Kathiresan; Karen L Mohlke; Erik Ingelsson; Gonçalo R Abecasis; Gina M Peloso; Stefan Gustafsson; Stavroula Kanoni; Andrea Ganna; Jin Chen; Martin L Buchkovich; Samia Mora; Jacques S Beckmann; Jennifer L Bragg-Gresham; Hsing-Yi Chang; Ayşe Demirkan; Heleen M Den Hertog; Ron Do; Louise A Donnelly; Georg B Ehret; Tõnu Esko; Mary F Feitosa; Teresa Ferreira; Krista Fischer; Pierre Fontanillas; Ross M Fraser; Daniel F Freitag; Deepti Gurdasani; Kauko Heikkilä; Elina Hyppönen; Aaron Isaacs; Anne U Jackson; Åsa Johansson; Toby Johnson; Marika Kaakinen; Johannes Kettunen; Marcus E Kleber; Xiaohui Li; Jian'an Luan; Leo-Pekka Lyytikäinen; Patrik K E Magnusson; Massimo Mangino; Evelin Mihailov; May E Montasser; Martina Müller-Nurasyid; Ilja M Nolte; Jeffrey R O'Connell; Cameron D Palmer; Markus Perola; Ann-Kristin Petersen; Serena Sanna; Richa Saxena; Susan K Service; Sonia Shah; Dmitry Shungin; Carlo Sidore; Ci Song; Rona J Strawbridge; Ida Surakka; Toshiko Tanaka; Tanya M Teslovich; Gudmar Thorleifsson; Evita G Van den Herik; Benjamin F Voight; Kelly A Volcik; Lindsay L Waite; Andrew Wong; Ying Wu; Weihua Zhang; Devin Absher; Gershim Asiki; Inês Barroso; Latonya F Been; Jennifer L Bolton; Lori L Bonnycastle; Paolo Brambilla; Mary S Burnett; Giancarlo Cesana; Maria Dimitriou; Alex S F Doney; Angela Döring; Paul Elliott; Stephen E Epstein; Gudmundur Ingi Eyjolfsson; Bruna Gigante; Mark O Goodarzi; Harald Grallert; Martha L Gravito; Christopher J Groves; Göran Hallmans; Anna-Liisa Hartikainen; Caroline Hayward; Dena Hernandez; Andrew A Hicks; Hilma Holm; Yi-Jen Hung; Thomas Illig; Michelle R Jones; Pontiano Kaleebu; John J P Kastelein; Kay-Tee Khaw; Eric Kim; Norman Klopp; Pirjo Komulainen; Meena Kumari; Claudia Langenberg; Terho Lehtimäki; Shih-Yi Lin; Jaana Lindström; Ruth J F Loos; François Mach; Wendy L McArdle; Christa Meisinger; Braxton D Mitchell; Gabrielle Müller; Ramaiah Nagaraja; Narisu Narisu; Tuomo V M Nieminen; Rebecca N Nsubuga; Isleifur Olafsson; Ken K Ong; Aarno Palotie; Theodore Papamarkou; Cristina Pomilla; Anneli Pouta; Daniel J Rader; Muredach P Reilly; Paul M Ridker; Fernando Rivadeneira; Igor Rudan; Aimo Ruokonen; Nilesh Samani; Hubert Scharnagl; Janet Seeley; Kaisa Silander; Alena Stančáková; Kathleen Stirrups; Amy J Swift; Laurence Tiret; Andre G Uitterlinden; L Joost van Pelt; Sailaja Vedantam; Nicholas Wainwright; Cisca Wijmenga; Sarah H Wild; Gonneke Willemsen; Tom Wilsgaard; James F Wilson; Elizabeth H Young; Jing Hua Zhao; Linda S Adair; Dominique Arveiler; Themistocles L Assimes; Stefania Bandinelli; Franklyn Bennett; Murielle Bochud; Bernhard O Boehm; Dorret I Boomsma; Ingrid B Borecki; Stefan R Bornstein; Pascal Bovet; Michel Burnier; Harry Campbell; Aravinda Chakravarti; John C Chambers; Yii-Der Ida Chen; Francis S Collins; Richard S Cooper; John Danesh; George Dedoussis; Ulf de Faire; Alan B Feranil; Jean Ferrières; Luigi Ferrucci; Nelson B Freimer; Christian Gieger; Leif C Groop; Vilmundur Gudnason; Ulf Gyllensten; Anders Hamsten; Tamara B Harris; Aroon Hingorani; Joel N Hirschhorn; Albert Hofman; G Kees Hovingh; Chao Agnes Hsiung; Steve E Humphries; Steven C Hunt; Kristian Hveem; Carlos Iribarren; Marjo-Riitta Järvelin; Antti Jula; Mika Kähönen; Jaakko Kaprio; Antero Kesäniemi; Mika Kivimaki; Jaspal S Kooner; Peter J Koudstaal; Ronald M Krauss; Diana Kuh; Johanna Kuusisto; Kirsten O Kyvik; Markku Laakso; Timo A Lakka; Lars Lind; Cecilia M Lindgren; Nicholas G Martin; Winfried März; Mark I McCarthy; Colin A McKenzie; Pierre Meneton; Andres Metspalu; Leena Moilanen; Andrew D Morris; Patricia B Munroe; Inger Njølstad; Nancy L Pedersen; Chris Power; Peter P Pramstaller; Jackie F Price; Bruce M Psaty; Thomas Quertermous; Rainer Rauramaa; Danish Saleheen; Veikko Salomaa; Dharambir K Sanghera; Jouko Saramies; Peter E H Schwarz; Wayne H-H Sheu; Alan R Shuldiner; Agneta Siegbahn; Tim D Spector; Kari Stefansson; David P Strachan; Bamidele O Tayo; Elena Tremoli; Jaakko Tuomilehto; Matti Uusitupa; Cornelia M van Duijn; Peter Vollenweider; Lars Wallentin; Nicholas J Wareham; John B Whitfield; Bruce H R Wolffenbuttel; Jose M Ordovas; Eric Boerwinkle; Colin N A Palmer; Unnur Thorsteinsdottir; Daniel I Chasman; Jerome I Rotter; Paul W Franks; Samuli Ripatti; L Adrienne Cupples; Manjinder S Sandhu; Stephen S Rich
Journal:  Nat Genet       Date:  2013-10-06       Impact factor: 38.330

View more
  8 in total

1.  Integrating hypertension phenotype and genotype with hybrid non-negative matrix factorization.

Authors:  Yuan Luo; Chengsheng Mao; Yiben Yang; Fei Wang; Faraz S Ahmad; Donna Arnett; Marguerite R Irvin; Sanjiv J Shah
Journal:  Bioinformatics       Date:  2019-04-15       Impact factor: 6.937

2.  Association of the FRMD5 rs2929282 polymorphism and serum lipid profiles in two Chinese ethnic groups.

Authors:  Hui Gao; Rui-Xing Yin; Qing-Hui Zhang; Ling Qiu; Eksavang Khounphinith; Duo-Shun Wang; Kai-Guang Li
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

3.  Proteomic analysis of the response of Trichinella spiralis muscle larvae to exogenous nitric oxide.

Authors:  Xiaoli Wang; Liang Li; Xing Wei; Yuanyuan Wang; Hui Zhang; Ao Shi; Tao Liu; Xiaodi Yang; Qiang Fang
Journal:  PLoS One       Date:  2018-06-05       Impact factor: 3.240

4.  Association between SLC44A4-NOTCH4 SNPs and serum lipid levels in the Chinese Han and Maonan ethnic groups.

Authors:  Peng-Fei Zheng; Rui-Xing Yin; Yao-Zong Guan; Bi-Liu Wei; Chun-Xiao Liu; Guo-Xiong Deng
Journal:  Nutr Metab (Lond)       Date:  2020-12-14       Impact factor: 4.169

Review 5.  Genetic Regulatory Networks of Apolipoproteins and Associated Medical Risks.

Authors:  Preethi Basavaraju; Rubadevi Balasubramani; Divya Sri Kathiresan; Ilakkiyapavai Devaraj; Kavipriya Babu; Vasanthakumar Alagarsamy; Vinayaga Moorthi Puthamohan
Journal:  Front Cardiovasc Med       Date:  2022-01-06

Review 6.  CAPN3: A muscle‑specific calpain with an important role in the pathogenesis of diseases (Review).

Authors:  Lin Chen; Fajuan Tang; Hu Gao; Xiaoyan Zhang; Xihong Li; Dongqiong Xiao
Journal:  Int J Mol Med       Date:  2021-09-22       Impact factor: 4.101

7.  The CXCL12 SNPs and their haplotypes are associated with serum lipid traits.

Authors:  Ling Qiu; Rui-Xing Yin; Rong-Jun Nie; Xi-Jiang Hu; Eksavang Khounphinith; Fen-Han Zhang
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

8.  Associations between TUBB-WWOX SNPs, their haplotypes, gene-gene, and gene-environment interactions and dyslipidemia.

Authors:  Chun-Xiao Liu; Rui-Xing Yin; Zong-Hu Shi; Peng-Fei Zheng; Guo-Xiong Deng; Yao-Zong Guan; Bi-Liu Wei
Journal:  Aging (Albany NY)       Date:  2021-02-17       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.